NCT04521751View on ClinicalTrials.gov

A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

May 7, 2020

Primary Completion Date

August 30, 2021

Study Completion Date

August 30, 2021

Conditions
Overweight or Obesity
Interventions
DRUG

EMP16-02 120 mg orlistat/40 mg acarbose

EMP16-02 capsules are composed of three pharmaceutical fractions (granules denoted G1, G2 and G3). G1= Prolonged release of acarbose, G2= Enteric-coated granule fraction containing orlistat and acarbose, G3= Orlistat with a delayed on-set release mechanism.

DRUG

EMP16-02 150 mg orlistat/50 mg acarbose

EMP16-02 capsules are composed of three pharmaceutical fractions (granules denoted G1, G2 and G3). G1= Prolonged release of acarbose, G2= Enteric-coated granule fraction containing orlistat and acarbose, G3= Orlistat with a delayed on-set release mechanism.

DRUG

Placebo

Matching oral placebo capsules

Trial Locations (2)

58758

Clinical Trial Consultants AB, Linköping

75237

Clinical Trial Consultants AB, Uppsala

Sponsors

Lead Sponsor

Empros Pharma AB
All Listed Sponsors
collaborator

CTC Clinical Trial Consultants AB

INDUSTRY

lead

Empros Pharma AB

INDUSTRY

NCT04521751 - A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary) | Biotech Hunter | Biotech Hunter